Incyte (INCY) Shares Outstanding (2010 - 2026)
Incyte (INCY) posted Shares Outstanding (Entity) of $199.9 million for Q1 2026, up 0.75% on a QoQ basis from $198.5 million in Q4 2025, and up 3.18% year-over-year from $193.8 million in Q1 2025.
Incyte (INCY) Shares Outstanding (2010 - 2026) Analysis & Trends
Incyte's Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $199.9 million for Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 3.18% year-over-year to $199.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $199.9 million (up 3.18% YoY) and the FY2025 annual result came in at $198.5 million, up 2.6% from the prior year.
- Shares Outstanding (Entity) was $199.9 million for Q1 2026 at Incyte, up from $198.5 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $224.5 million in Q1 2024 and bottomed at $191.6 million in Q2 2024.
- A 5-year average of $209.9 million and a median of $221.4 million in 2022 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) declined 14.22% — and 2026, when it climbed 3.18%.
- Incyte's Shares Outstanding (Entity) stood at $222.7 million in 2022, then advanced by 0.69% to $224.3 million in 2023, then slipped by 13.76% to $193.4 million in 2024, then gained by 2.6% to $198.5 million in 2025, then gained by 0.75% to $199.9 million in 2026.
- Business Quant data shows INCY's Shares Outstanding (Entity) at $199.9 million in Q1 2026, $198.5 million in Q4 2025, and $196.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 6,012.74 Bn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 47.82 Bn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 118.76 Bn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.44 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 254.10 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 400.00 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 62.06 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 198.10 Mn |
| 10 | Incyte | 23.47 Bn | 19.46 Bn | 1.17 Bn | 199.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 199.34 Mn |
| Dec 31, 2025 | 195.20 Mn |
| Sep 30, 2025 | 195.67 Mn |
| Jun 30, 2025 | 194.00 Mn |
| Mar 31, 2025 | 193.71 Mn |
| Dec 31, 2024 | 207.11 Mn |
| Sep 30, 2024 | 192.63 Mn |
| Jun 30, 2024 | 218.18 Mn |
| Mar 31, 2024 | 224.48 Mn |
| Dec 31, 2023 | 223.63 Mn |
| Sep 30, 2023 | 224.08 Mn |
| Jun 30, 2023 | 223.25 Mn |
| Mar 31, 2023 | 222.96 Mn |
| Dec 31, 2022 | 222.00 Mn |
| Sep 30, 2022 | 222.42 Mn |
| Jun 30, 2022 | 221.66 Mn |
| Mar 31, 2022 | 221.33 Mn |
| Dec 31, 2021 | 220.43 Mn |
| Sep 30, 2021 | 220.85 Mn |
| Jun 30, 2021 | 220.08 Mn |